SG11201510376QA - Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors - Google Patents
Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitorsInfo
- Publication number
- SG11201510376QA SG11201510376QA SG11201510376QA SG11201510376QA SG11201510376QA SG 11201510376Q A SG11201510376Q A SG 11201510376QA SG 11201510376Q A SG11201510376Q A SG 11201510376QA SG 11201510376Q A SG11201510376Q A SG 11201510376QA SG 11201510376Q A SG11201510376Q A SG 11201510376QA
- Authority
- SG
- Singapore
- Prior art keywords
- phenylethylidene
- substituted
- histone demethylase
- demethylase inhibitors
- benzohydrazide analogs
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- HAUVWRQIVOPGOE-FOWTUZBSSA-N n-[(e)-1-phenylethylideneamino]benzamide Chemical class C=1C=CC=CC=1C(/C)=N/NC(=O)C1=CC=CC=C1 HAUVWRQIVOPGOE-FOWTUZBSSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/921,895 US9266838B2 (en) | 2011-08-15 | 2013-06-19 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| PCT/US2014/043179 WO2014205213A1 (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510376QA true SG11201510376QA (en) | 2016-01-28 |
Family
ID=52105283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201710543PA SG10201710543PA (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| SG11201510376QA SG11201510376QA (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201710543PA SG10201710543PA (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3010915B1 (en) |
| JP (1) | JP6525162B2 (en) |
| KR (1) | KR102288648B1 (en) |
| CN (2) | CN110015984A (en) |
| AU (1) | AU2014281398B2 (en) |
| BR (1) | BR112015032113B1 (en) |
| CA (1) | CA2915817C (en) |
| ES (1) | ES2739814T3 (en) |
| IL (1) | IL243200B (en) |
| MX (1) | MX366949B (en) |
| NZ (1) | NZ715331A (en) |
| SG (2) | SG10201710543PA (en) |
| WO (1) | WO2014205213A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3010915B1 (en) * | 2013-06-19 | 2019-05-08 | University of Utah Research Foundation | Substituted (3-(5-chloro-2-hydroxyphenyl)-1-benzoyl-1h-pyrazole compounds as histone demethylase inhibitors |
| ME03654B (en) | 2014-02-13 | 2020-07-20 | Incyte Corp | CYCLOPROPYLAMINE AS LSD1 INHIBITORS |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| PT3105226T (en) | 2014-02-13 | 2019-11-06 | Incyte Corp | CYCLOPROPYLAMINS AS LSD1 INHIBITORS |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016119031A1 (en) * | 2015-01-29 | 2016-08-04 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Compound, method for synthetising the compound, use, pharmaceutical composition, method for treatment of inflammation or neurodegenerative disease, oral dosage form and method for inhibiting the acetylcholinesterase enzyme |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| CA2987876A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| KR102710120B1 (en) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Salt of LSD1 inhibitor |
| SG11201805451TA (en) | 2015-12-30 | 2018-07-30 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| CN120661674A (en) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | Combination of LSD1 inhibitors for the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| AR109452A1 (en) | 2016-04-22 | 2018-12-12 | Incyte Corp | PHARMACEUTICAL FORMULATION OF AN LSD1 INHIBITOR AND TREATMENT METHOD |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| CN108727377A (en) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3- cyano pyrazoles simultaneously [1,5-a] pyrimidine derivatives and its preparation method and application |
| SI3661510T1 (en) | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | Lsd1 inhibitors for the treatment and prevention of cardiomyopathies |
| CN108689960B (en) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-benzylidene-2-phenyl thiazolone compound and preparation and application thereof |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| KR20210141933A (en) | 2019-03-20 | 2021-11-23 | 오리존 지노믹스 에스.에이. | How to treat borderline personality disorder |
| MX2021011254A (en) | 2019-03-20 | 2021-10-01 | Oryzon Genomics Sa | METHODS OF TREATMENT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER. |
| EP3994280A1 (en) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| CN111426850B (en) * | 2020-01-15 | 2021-12-21 | 上海众启生物科技有限公司 | Composition containing DNAJC8 protein fragment for detecting Alzheimer's disease autoantibody |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| BR112023020554A2 (en) | 2021-04-08 | 2023-12-05 | Oryzon Genomics Sa | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF MYELOID CANCERS |
| JP2025516647A (en) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Treatment of malignant peripheral nerve sheath tumors (MPNST) using LSD1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116444437B (en) * | 2023-03-08 | 2025-09-16 | 曲靖师范学院 | Synthesis method of anti-cancer medicine dalsulamide |
| CN116813569B (en) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | Preparation method of anticancer drug intermediate and preparation method of anticancer drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005022113D1 (en) * | 2005-01-07 | 2010-08-12 | Hoffmann La Roche | PHENYL) METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRICAL DISEASES |
| WO2006136008A1 (en) * | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| WO2007008143A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| EP2376436A2 (en) * | 2009-01-14 | 2011-10-19 | Dow AgroSciences LLC | Fungicidal compositions including hydrazone derivatives and copper |
| WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
| US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
| CA2815330A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2744330B1 (en) | 2011-08-15 | 2020-07-15 | University of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| EP3010915B1 (en) * | 2013-06-19 | 2019-05-08 | University of Utah Research Foundation | Substituted (3-(5-chloro-2-hydroxyphenyl)-1-benzoyl-1h-pyrazole compounds as histone demethylase inhibitors |
-
2014
- 2014-06-19 EP EP14813387.9A patent/EP3010915B1/en not_active Not-in-force
- 2014-06-19 JP JP2016521574A patent/JP6525162B2/en not_active Expired - Fee Related
- 2014-06-19 MX MX2015018032A patent/MX366949B/en active IP Right Grant
- 2014-06-19 BR BR112015032113-5A patent/BR112015032113B1/en not_active IP Right Cessation
- 2014-06-19 ES ES14813387T patent/ES2739814T3/en active Active
- 2014-06-19 SG SG10201710543PA patent/SG10201710543PA/en unknown
- 2014-06-19 WO PCT/US2014/043179 patent/WO2014205213A1/en not_active Ceased
- 2014-06-19 CN CN201910116764.XA patent/CN110015984A/en active Pending
- 2014-06-19 CA CA2915817A patent/CA2915817C/en active Active
- 2014-06-19 NZ NZ71533114A patent/NZ715331A/en not_active IP Right Cessation
- 2014-06-19 AU AU2014281398A patent/AU2014281398B2/en not_active Ceased
- 2014-06-19 CN CN201480045891.0A patent/CN105555784B/en not_active Expired - Fee Related
- 2014-06-19 KR KR1020167001538A patent/KR102288648B1/en not_active Expired - Fee Related
- 2014-06-19 SG SG11201510376QA patent/SG11201510376QA/en unknown
-
2015
- 2015-12-17 IL IL243200A patent/IL243200B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP6525162B2 (en) | 2019-06-05 |
| CA2915817A1 (en) | 2014-12-24 |
| AU2014281398B2 (en) | 2018-10-04 |
| IL243200B (en) | 2020-10-29 |
| EP3010915A1 (en) | 2016-04-27 |
| IL243200A0 (en) | 2016-02-29 |
| CN110015984A (en) | 2019-07-16 |
| EP3010915A4 (en) | 2016-12-28 |
| MX2015018032A (en) | 2016-10-03 |
| WO2014205213A1 (en) | 2014-12-24 |
| SG10201710543PA (en) | 2018-02-27 |
| KR20160024929A (en) | 2016-03-07 |
| JP2016523256A (en) | 2016-08-08 |
| CN105555784B (en) | 2019-03-15 |
| MX366949B (en) | 2019-07-30 |
| EP3010915B1 (en) | 2019-05-08 |
| CA2915817C (en) | 2022-12-13 |
| BR112015032113A2 (en) | 2017-03-21 |
| AU2014281398A1 (en) | 2016-01-21 |
| CN105555784A (en) | 2016-05-04 |
| ES2739814T3 (en) | 2020-02-04 |
| NZ715331A (en) | 2019-09-27 |
| BR112015032113B1 (en) | 2019-01-29 |
| KR102288648B1 (en) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243200A0 (en) | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors | |
| ZA201400881B (en) | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhiitors | |
| EP2970211A4 (en) | HISTONE DEMETHYLASE INHIBITORS | |
| EP2968282A4 (en) | HISTONE DEMETHYLASE INHIBITORS | |
| IL241165A0 (en) | Biaryl amide compounds as kinase inhibitors | |
| EP2935217A4 (en) | HISTONE DEMETHYLASE INHIBITORS | |
| EP2934145A4 (en) | HISTONE DEMETHYLASE INHIBITORS | |
| IL242388B (en) | Novel histone deacetylase inhibitors | |
| DK2920149T3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA T INHIBITORS AND USES THEREOF | |
| DK2968443T3 (en) | HEPCIDINE ANALOGS AND USES THEREOF | |
| EP2881386A4 (en) | AMIDE COMPOUND | |
| LT3702351T (en) | COMPOSITIONS COMPRISING MEK INHIBITORS | |
| EP3006444A4 (en) | HETEROCYCLIC AMIDE COMPOUND | |
| EP2842937A4 (en) | AMINO COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | |
| ES1078469Y (en) | DISINCRUSTING HEAD FOR MOPS | |
| EP3006443A4 (en) | BENZOTHIOPHENE COMPOUND | |
| ES1106280Y (en) | Jewel bracelet-bracelet for physical exercise |